Mather Group’s Mirum Pharmaceuticals MIRM Stock Holding History

Mather Group’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$940	Buy	+11	New	+$1.15K	﹤0.01%	2150

Other funds holding MIRM

Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return

Secure Asset Management Troy, Michigan $753M AUM 20.9% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

AMI Asset Management Los Angeles, California $1.74B AUM 24.77% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Juncture Wealth Strategies Scottsdale, Arizona $390M AUM 19.15% 1-Year Est. Return

NorthCrest Asset Manangement Plymouth, Minnesota $4.24B AUM 32.82% 1-Year Est. Return

Contravisory Investment Management Norwell, Massachusetts $552M AUM 32.44% 1-Year Est. Return

Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return

WIA

Wetzel Investment Advisors Indianapolis, Indiana $290M AUM 16.64% 1-Year Est. Return

Mather Group's MIRM Position: Q3 2026 in Review

Mather Group opened a new position in Mirum Pharmaceuticals (MIRM) in Q3 2026: 11 shares worth $940. The stake represents ﹤0.01% of the portfolio and ranks #2150 among its holdings.

33 funds tracked by Wall St. Rank hold MIRM as of Q3 2026.

Mather Group held 11 shares of Mirum Pharmaceuticals worth $940 as of Q3 2026.
Mirum Pharmaceuticals was a new Mather Group position in Q3 2026.
Mirum Pharmaceuticals made up ﹤0.01% of Mather Group's portfolio in Q3 2026, its #2150 holding.
33 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q3 2026.

Based on Mather Group's 13F filing for Q3 2026, filed 14 Oct 2026.